[go: up one dir, main page]

NO995996D0 - Fremgangsmåte for behandling av fedme - Google Patents

Fremgangsmåte for behandling av fedme

Info

Publication number
NO995996D0
NO995996D0 NO995996A NO995996A NO995996D0 NO 995996 D0 NO995996 D0 NO 995996D0 NO 995996 A NO995996 A NO 995996A NO 995996 A NO995996 A NO 995996A NO 995996 D0 NO995996 D0 NO 995996D0
Authority
NO
Norway
Prior art keywords
treating obesity
obesity
treating
Prior art date
Application number
NO995996A
Other languages
English (en)
Other versions
NO995996L (no
NO324818B1 (no
Inventor
Bradford J Duft
Orville G Kolterman
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of NO995996D0 publication Critical patent/NO995996D0/no
Publication of NO995996L publication Critical patent/NO995996L/no
Publication of NO324818B1 publication Critical patent/NO324818B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19995996A 1997-06-06 1999-12-06 Anvendelse av amylin eller en amylinagonist NO324818B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/870,762 US7910548B2 (en) 1997-06-06 1997-06-06 Methods for treating obesity
PCT/US1998/011753 WO1998055144A1 (en) 1997-06-06 1998-06-05 Methods for treating obesity

Publications (3)

Publication Number Publication Date
NO995996D0 true NO995996D0 (no) 1999-12-06
NO995996L NO995996L (no) 2000-02-07
NO324818B1 NO324818B1 (no) 2007-12-10

Family

ID=25356022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19995996A NO324818B1 (no) 1997-06-06 1999-12-06 Anvendelse av amylin eller en amylinagonist

Country Status (10)

Country Link
US (1) US7910548B2 (no)
AU (1) AU7823098A (no)
BR (1) BR9809951A (no)
CZ (1) CZ294983B6 (no)
HU (1) HUP0004271A3 (no)
NO (1) NO324818B1 (no)
NZ (1) NZ501451A (no)
PL (1) PL193236B1 (no)
RU (2) RU2207871C2 (no)
WO (1) WO1998055144A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739020B2 (en) * 1997-01-07 2001-10-04 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20040022807A1 (en) * 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
JP4353544B2 (ja) * 1998-01-09 2009-10-28 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリン作動薬ペプチド用製剤
ES2316757T3 (es) * 2002-01-08 2009-04-16 Amylin Pharmaceuticals, Inc. Uso de agonistas de amilina para modular trigliceridos.
WO2005021026A2 (en) * 2003-08-29 2005-03-10 Amylin Pharmaceuticals, Inc. Methods for treating or ameliorating ghrelin-associated diseases and disorders
EP2422806A3 (en) 2004-02-11 2012-06-13 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
EP2286837A3 (en) † 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and obesity related diseases
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
JP2010531828A (ja) * 2007-06-29 2010-09-30 ロンザ アーゲー プラムリンチドの製造方法
RU2403038C2 (ru) * 2008-09-18 2010-11-10 Общество с ограниченной ответственностью "Идеи для здоровья. Группа компаний" Способ лечения и/или профилактики избыточной массы тела, и/или ожирения, и/или метаболических нарушений
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
RU2552221C2 (ru) * 2010-07-15 2015-06-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
RU2523558C2 (ru) * 2012-08-22 2014-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Россиской Федерации Способ лечения и повышения качества жизни больных с синдромом диспепсии в сочетании с ожирением
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
US20230158116A1 (en) * 2020-04-20 2023-05-25 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443619A (en) * 1978-12-26 1984-04-17 Hoffmann-La Roche Inc. Chlorocitric acids
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5367052A (en) 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5280014A (en) * 1988-01-11 1994-01-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
JPH04500688A (ja) * 1989-07-10 1992-02-06 アミリン・コーポレイション 肥満および本態性高血圧および関連疾患の治療
AU7316591A (en) * 1990-02-28 1991-09-18 Upjohn Company, The Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
AU7691291A (en) * 1990-05-02 1991-11-27 Upjohn Company, The Method of treating gastric ulcers and obesity
SE466130B (sv) * 1990-11-22 1992-01-07 Kabi Pharmacia Ab Gelbildande flytande dietfiberkomposition
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1992015317A1 (en) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
DK0586589T3 (da) 1991-05-24 1997-09-22 Amylin Pharmaceuticals Inc Amylin- eller amylinanalogpræparat, som eventuelt indeholder insulin, til behandling af anoreksi og beslægtede tilstande
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
SK88793A3 (en) 1991-11-19 1994-12-07 Amylin Pharmaceuticals Inc Amylin agonising peptides and their using
JP2662094B2 (ja) * 1992-01-21 1997-10-08 アボツト・ラボラトリーズ ４″−デオキシエリスロマイシン誘導体
US5376638A (en) 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
PL307138A1 (en) * 1993-05-12 1995-05-02 Univ Cincinnati Amyline antagonists and agonists
DE69426304T2 (de) * 1993-09-07 2001-03-15 Amylin Pharmaceuticals, Inc. Methoden zur regulation der den magen und darm betreffenden motilitaet
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
SK281433B6 (sk) * 1994-04-14 2001-03-12 Glaxo Wellcome Inc. 5-heterocyklo-1,5-benzodiazepínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity
TW448046B (en) * 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
US5766851A (en) * 1995-05-19 1998-06-16 The Johns Hopkins University School Of Medicine Susceptibility gene for obesity and type II diabetes mellitus
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5646040A (en) * 1995-06-30 1997-07-08 Millennium Pharmaceutical, Inc. Mammalian tub gene
RU2060012C1 (ru) * 1995-08-07 1996-05-20 Ирина Львовна Медкова Способ профилактики и лечения заболеваний, связанных с нарушением липидного обмена
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US5690691A (en) * 1996-05-08 1997-11-25 The Center For Innovative Technology Gastro-intestinal pacemaker having phased multi-point stimulation
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US5965607A (en) * 1996-12-30 1999-10-12 American Home Products Corporation Substituted Benzo[1,4]dioxines as antiobesity agents
AU739020B2 (en) * 1997-01-07 2001-10-04 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
US5955443A (en) * 1998-03-19 1999-09-21 Isis Pharmaceuticals Inc. Antisense modulation of PECAM-1
US6100047A (en) * 1999-04-07 2000-08-08 Zen Bio, Inc. Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition

Also Published As

Publication number Publication date
PL338082A1 (en) 2000-09-25
CZ294983B6 (cs) 2005-04-13
AU7823098A (en) 1998-12-21
HUP0004271A3 (en) 2001-08-28
NO995996L (no) 2000-02-07
NZ501451A (en) 2001-10-26
RU2314121C9 (ru) 2008-08-10
US7910548B2 (en) 2011-03-22
PL193236B1 (pl) 2007-01-31
RU2207871C2 (ru) 2003-07-10
HUP0004271A2 (hu) 2001-05-28
US20030026812A1 (en) 2003-02-06
BR9809951A (pt) 2000-08-01
NO324818B1 (no) 2007-12-10
RU2314121C2 (ru) 2008-01-10
CZ9904360A3 (cs) 2000-10-11
WO1998055144A1 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
NO995996L (no) Fremgangsmåte for behandling av fedme
NO974554D0 (no) Fremgangsmåte for behandling av en underjordisk formasjon
EP0973461A4 (en) MIGRAINE TREATMENT
NO986052D0 (no) Antikonvulsive derivater for behandling av fedme
NO991955D0 (no) FremgangsmÕte for behandling av hydrokarboner
NO20010117D0 (no) Fremgangsmåte for behandling av sövnlöshet
NO975159L (no) Fremgangsmåte for kontroll av biologisk nedbrytning
NO973009D0 (no) Fremgangsmåte for å inhibere kathepsin-k
NO20003065L (no) Kombinasjon for effektiv behandling av impotens
FI963526L (fi) Menetelmä jätemateriaalin termistä käsittelyä varten
NO982911D0 (no) FremgangsmÕte for behandling av depresjon
IS5384A (is) Aðferð til meðferðar á hreyfingartregðu sem er tengd sjúkdómi eða framkölluð með lyfjum
DE69717846D1 (de) Behandlungsverfahren von laktamen
FI973173L (fi) Menetelmä kondensaatin käsittelemiseksi
ID18300A (id) Metoda penemperan
NO982582D0 (no) FremgangsmÕte for behandling av smerte
PL341667A1 (en) Method of treating cooped
DE69812599D1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis
NO20006383L (no) Fremgangsmåte for behandling
NO980588D0 (no) Fremgangsmåte for behandling av vann
UA25504A (uk) Спосіб лікуваhhя дисбактеріозу hосоглотки
NO995797D0 (no) Fremgangsmåte for behandling av isolert systolisk hypertensjon
UA25577A (uk) Спосіб обробки голиhи
UA25636A (uk) Спосіб лікуваhhя hеврозів
UA25349A (uk) Спосіб лікуваhhя гострого деструктивhого паhкреатиту

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTRAZENECA PHARMACEUTICALS LP, US

MM1K Lapsed by not paying the annual fees